List of Excipients in Branded Drug LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

Generic Drugs Containing LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

Company	Ingredient	NDC	Excipient
WALGREEN CO	loperamide hydrochloride and simethicone	0363-9606	ACESULFAME POTASSIUM
WALGREEN CO	loperamide hydrochloride and simethicone	0363-9606	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
WALGREEN CO	loperamide hydrochloride and simethicone	0363-9606	CROSCARMELLOSE SODIUM
WALGREEN CO	loperamide hydrochloride and simethicone	0363-9606	MICROCRYSTALLINE CELLULOSE 101
WALGREEN CO	loperamide hydrochloride and simethicone	0363-9606	MICROCRYSTALLINE CELLULOSE 102
WALGREEN CO	loperamide hydrochloride and simethicone	0363-9606	STEARIC ACID
Better Living Brands LLC	loperamide hydrochloride and simethicone	21130-222	ACESULFAME POTASSIUM

What are the Most Frequently-Used Excipients in LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE?

# Of NDCs	Excipient
15	ACESULFAME POTASSIUM
11	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
4	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
7	CELLULOSE, MICROCRYSTALLINE
15	CROSCARMELLOSE SODIUM
1	MALTODEXTRIN
8	MICROCRYSTALLINE CELLULOSE 101

Loperamide Hydrochloride and Simethicone Excipient Strategy and Commercial Opportunity

Last updated: August 8, 2026

Loperamide hydrochloride and simethicone is a mature over-the-counter combination for diarrhea accompanied by gas, bloating, or cramping. The core commercial opportunity is not exclusivity on the active ingredients. It is differentiated delivery, manufacturability, consumer usability, private-label economics, and compliance with the FDA’s nonprescription drug framework.

The standard U.S. combination contains loperamide hydrochloride 2 mg and simethicone 125 mg per caplet or tablet. Loperamide reduces intestinal motility and fluid loss. Simethicone reduces surface tension of gas bubbles and helps relieve pressure and bloating. The combination is marketed under branded and store-brand products, including Imodium Multi-Symptom Relief and equivalent products.

The strongest excipient strategy is a low-cost, rapidly disintegrating solid oral dosage form with robust moisture control, acceptable mouthfeel, high tablet hardness, and efficient packaging. A premium opportunity exists in orally disintegrating, chewable, liquid-filled, pediatric-restricted, or travel-oriented formats, although each option creates additional regulatory, stability, and manufacturing requirements.

What is the FDA regulatory status of loperamide hydrochloride and simethicone?

The combination is an OTC product regulated primarily through FDA nonprescription drug rules rather than through new-drug exclusivity.

Loperamide hydrochloride is addressed under the FDA OTC antidiarrheal monograph framework in 21 C.F.R. Part 335. Simethicone is addressed under the FDA OTC antiflatulent monograph framework in 21 C.F.R. Part 332. Product labeling, dosage, warnings, active-ingredient levels, and claims must comply with the applicable monograph provisions or another valid FDA pathway.[1,2]

Regulatory element	Commercial implication
Active ingredients	Loperamide hydrochloride and simethicone have long-established OTC use
Primary FDA pathway	OTC monograph compliance or an approved application
Dosage form	Usually caplet, tablet, or softgel
Typical strength	Loperamide HCl 2 mg plus simethicone 125 mg
Therapeutic claims	Diarrhea relief plus gas, pressure, or bloating relief
Prescription-drug exclusivity	Generally not the principal commercial barrier
Biosimilar pathway	Not applicable because the product is a small-molecule combination
Main regulatory risks	Labeling, abuse-related warnings, dosage errors, quality, and monograph compliance

Loperamide carries important misuse and abuse-related safety concerns at excessive doses. FDA has warned that large quantities can cause severe cardiac events, including QT prolongation, syncope, cardiac arrest, and death.[3] Packaging, label warnings, maximum daily dose, and unit-dose control therefore have commercial and regulatory importance.

What patents protect loperamide hydrochloride and simethicone products?

The active ingredients are old, and their basic composition-of-matter protection has expired. A commercially relevant U.S. product does not depend on a current patent covering loperamide hydrochloride or simethicone as chemical entities.

Protection may still arise from narrower rights involving:

• Specific dosage forms
• Modified-release delivery
• Taste-masking systems
• Orally disintegrating tablets
• Chewable or liquid formulations
• Bilayer or multilayer tablets
• Moisture-resistant packaging
• Manufacturing processes
• Combination claims
• Labeling or method-of-use claims
• Product trademarks and trade dress

A routine immediate-release tablet containing 2 mg loperamide hydrochloride and 125 mg simethicone is unlikely to have a strong blocking patent position solely because of the active-ingredient combination. The commercial barrier is more likely to be manufacturing scale, brand recognition, retail placement, quality consistency, and supply economics.

What is the Orange Book status of the combination?

The FDA Orange Book primarily lists approved prescription drug products and certain approved applications. OTC monograph products generally do not receive the same Orange Book listing profile as prescription products approved through an NDA.[4]

For a loperamide hydrochloride and simethicone OTC product, the practical conclusion is:

1. The product is not normally protected by an Orange Book-listed patent in the manner of a branded prescription drug.
2. A conventional Paragraph IV strategy is usually not the central entry route for a monograph-compliant OTC product.
3. A sponsor seeking approval outside the monograph framework could face application-specific patent certification issues, but that is distinct from the ordinary private-label or generic OTC pathway.
4. Trademark, packaging, distribution, and supply arrangements can remain enforceable even when active-ingredient patent protection has expired.

A company should not treat the absence of an Orange Book patent listing as evidence that every formulation or delivery technology is free of third-party patent risk. It means the relevant risk must be assessed through broader patent searching, including formulation, process, packaging, and foreign rights.

When does loperamide hydrochloride and simethicone lose exclusivity?

The active ingredients have already lost chemical exclusivity. No meaningful new-chemical-entity exclusivity remains for either ingredient.

Exclusivity category	Status
Loperamide chemical patent	Expired
Simethicone composition protection	Expired or not commercially relevant as a blocking right
Prescription NCE exclusivity	Not applicable to the mature OTC combination
OTC monograph eligibility	Public regulatory framework remains available
Brand trademark	May remain active indefinitely if maintained and used
Formulation patents	Possible, but scope depends on claims and expiration
Trade secret protection	May continue for manufacturing and coating processes

The commercial lifecycle is therefore open-ended. Retailers can launch store brands, contract manufacturers can supply equivalent products, and branded companies can compete through formulation, packaging, dosing convenience, and marketing.

What excipients are used in loperamide and simethicone tablets?

Exact excipients differ by manufacturer, dosage form, and market. A conventional immediate-release caplet may contain a filler system, binder, disintegrant, lubricant, coating polymer, pigment, and processing aid.

Typical excipient classes include:

Excipient function	Common options	Role in the product
Diluent	Microcrystalline cellulose, dibasic calcium phosphate, mannitol	Provides tablet mass and compression properties
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid breakup after ingestion
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction and sticking
Glidant	Colloidal silicon dioxide	Improves powder flow
Sweetener	Sucralose, saccharin sodium, mannitol	Supports chewable or orally disintegrating formats
Flavor	Mint, fruit, or neutral flavor systems	Improves consumer acceptance
Film coating	Hypromellose, polyethylene glycol, pigments	Controls appearance, swallowability, and handling
Wetting aid	Polysorbates or surfactant systems where justified	Supports dispersion of simethicone
Moisture barrier	Polymer film, foil blister, desiccant packaging	Limits degradation and packaging-related defects

Simethicone is a hydrophobic mixture of polydimethylsiloxane and silicon dioxide. Its poor water dispersibility creates a central formulation issue. In a compressed tablet, the formulation must distribute simethicone consistently without causing sticking, segregation, variable dissolution behavior, or poor content uniformity.

Loperamide hydrochloride is present at a low dose relative to the excipient mass. Blend uniformity is therefore a critical process attribute. Direct compression can be economical, but it requires a powder system with suitable flow and segregation resistance. Roller compaction or wet granulation may improve uniformity and tablet robustness but adds equipment, validation, and cost.

What excipient strategy is best for an immediate-release caplet?

For a mass-market product, the preferred strategy is usually a conventional immediate-release caplet with:

• A robust direct-compression or dry-granulation platform
• A high-performing superdisintegrant
• A low-level lubricant system
• A film coat that improves swallowability without slowing disintegration
• A moisture-resistant blister or bottle
• A blend design that prevents loperamide segregation from the larger simethicone-containing fraction

A practical target profile is rapid disintegration, acceptable hardness, low friability, stable simethicone dispersion, and reliable assay uniformity through the product shelf life.

Calcium phosphate can provide strong compaction and low cost. Microcrystalline cellulose can improve binding and tablet structure. Crospovidone or croscarmellose sodium can support fast disintegration. Magnesium stearate is economical but requires controlled mixing because excessive lubrication can reduce tablet strength and slow wetting.

The formulation should avoid unnecessary excipient complexity. Each added excipient increases supplier qualification, regulatory documentation, allergen review, and change-control burden. A short excipient list also helps private-label customers support multiple markets.

What formulations are protected or commercially differentiated?

The strongest commercial differentiation is likely to come from delivery format rather than from a standard tablet composition.

Orally disintegrating tablets

An orally disintegrating tablet can address consumers who have difficulty swallowing or need treatment while traveling. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking systems may be useful. The main risks are:

• Bitter or medicinal loperamide taste
• Simethicone mouthfeel
• Low tablet strength
• Moisture sensitivity
• Packaging cost
• Dose uniformity at low drug load

A successful orally disintegrating formulation may support patent claims if it uses a genuinely novel taste-masking, porous matrix, or manufacturing process. Patent strength would depend on claim breadth and prior art, not on the dosage form label alone.

Chewable tablets

Chewables offer a stronger consumer proposition but create significant taste and texture requirements. Simethicone can produce a waxy or slippery sensation, while loperamide requires effective taste masking. Sweeteners, flavors, coated particles, lipid barriers, or ion-exchange systems can be evaluated.

Chewables may command a higher retail price but often have higher tooling, sensory, and packaging costs than standard caplets.

Softgels

A softgel may improve swallowability and enable a smooth visual product. It is less attractive when simethicone distribution and loperamide solubilization are difficult. Softgels also introduce shell compatibility, fill viscosity, oxygen exposure, and leakage considerations.

Liquid and suspension products

A liquid combination could appeal to selected adult consumers, but loperamide dosing accuracy and simethicone dispersion are difficult. Preservatives, suspending agents, flavor systems, and dose-measuring devices increase cost and regulatory complexity. Pediatric positioning is constrained by safety concerns and labeling requirements.

How strong is the patent estate for this drug combination?

The patent estate is likely weak for a basic immediate-release combination and potentially moderate for a technically differentiated delivery system.

IP layer	Likely strength	Commercial relevance
Active-ingredient patents	Low	Expired
Basic combination claim	Low to moderate	Vulnerable to prior art and obviousness challenges
Conventional tablet excipient composition	Low	Easy to design around
Taste-masked chewable	Moderate	Depends on formulation specificity
Orally disintegrating system	Moderate	May protect manufacturing and performance parameters
Modified-release system	Moderate to high	Relevant only if clinically and commercially needed
Packaging and moisture-control design	Low to moderate	Often narrow but useful operationally
Trademark and trade dress	High for branded products	Can sustain retail differentiation
Manufacturing know-how	Moderate to high	Difficult to replicate at scale without process development

A patent filing should focus on measurable technical advantages, such as improved content uniformity, reduced simethicone segregation, faster disintegration, improved stability, better taste masking, or reduced tablet weight. Broad claims covering ordinary excipient substitutions are more vulnerable to invalidity and design-around strategies.

What generic entry risks exist for loperamide and simethicone?

Generic entry risk is high because the active ingredients are old, the product is widely understood, and the OTC framework supports multiple suppliers.

The main entry scenarios are:

1. A retailer launches a monograph-compliant store brand.
2. A contract manufacturer supplies several national or regional labels.
3. A branded company introduces a differentiated format, such as chewable or orally disintegrating tablets.
4. A foreign manufacturer enters selected markets through local regulatory pathways.
5. A supplement or wellness product competes for gas-relief demand, although it cannot make equivalent drug claims without satisfying applicable requirements.

The principal barriers are operational rather than patent-based. These include validated low-dose blending, simethicone handling, finished-product testing, packaging reliability, and reliable access to active pharmaceutical ingredients.

Which companies are challenging the branded market?

The competitive landscape includes:

• Branded OTC manufacturers
• Retail pharmacy private-label divisions
• Supermarket and mass-merchant store brands
• Contract development and manufacturing organizations
• Regional generic OTC companies
• E-commerce sellers using third-party manufacturing

Imodium has strong consumer recognition in the diarrhea category, but private-label products can compete effectively because the indication is familiar and the active ingredients are standardized. Retailers can use lower prices, multipack formats, and shelf adjacency to capture demand.

A supplier with a validated formulation platform can create value by offering multiple strengths, package counts, and dosage forms from one manufacturing process. The most attractive customers are retailers seeking dual sourcing, branded companies seeking line extensions, and distributors serving travel, institutional, or international channels.

What licensing deals and commercial partnerships matter?

Licensing opportunities are more likely to involve formulation technology, manufacturing capacity, or brand rights than active-ingredient patents.

Potential transaction structures include:

• Formulation licensing for an orally disintegrating or chewable product
• Contract manufacturing with exclusive retail supply
• Private-label development agreements
• Regional trademark licensing
• Co-development of a premium travel pack
• Technology transfer for low-dose blend uniformity
• Dual-source supply agreements
• Acquisition of an established OTC brand with distribution access

The highest-value asset is often a regulatory-ready, scalable product platform with stable supply and retailer acceptance. A formulation patent can improve negotiating leverage, but a narrow patent without manufacturing scale or distribution is unlikely to support a large premium.

What revenue exposure does the product create?

Product-specific revenue figures are generally not disclosed separately by large OTC companies. Public companies typically report broader consumer-health, digestive-health, or gastrointestinal categories rather than individual SKU revenue.

Commercial exposure depends on:

• Retail price and gross margin
• Store-brand penetration
• Package count
• Seasonal diarrhea demand
• Travel-related demand
• Distribution through pharmacies, supermarkets, mass retailers, and e-commerce
• Promotional spending
• Active-ingredient and packaging costs
• Product recalls or warning-related label changes

The combination may generate higher per-unit revenue than loperamide alone because it addresses two consumer symptoms. That benefit must be balanced against higher formulation complexity and potential consumer confusion over dosing.

What manufacturing and IP barriers affect launch timing?

A standard caplet can have a relatively short development path when the formulation is monograph-compliant and the manufacturer has established facilities. The principal development work includes:

• Excipient compatibility
• Simethicone dispersion
• Loperamide blend uniformity
• Tablet compression and coating
• Disintegration and dissolution
• Accelerated and long-term stability
• Packaging qualification
• Label and claims review
• Process validation
• Supplier qualification

A differentiated product may require a longer program because taste masking, stability, dissolution, and consumer testing become central. Blister packaging may improve moisture protection and unit-dose control but increase packaging cost. Bottles reduce unit cost but may create counting, child-resistance, and moisture challenges.

How does loperamide and simethicone compare with loperamide alone?

Attribute	Loperamide alone	Loperamide plus simethicone
Primary benefit	Diarrhea control	Diarrhea control plus gas relief
Formulation complexity	Lower	Higher due to simethicone dispersion
Consumer proposition	Narrower	Broader symptom coverage
Retail price potential	Lower to moderate	Moderate
Patent opportunity	Limited	Some opportunity in combination delivery
Generic competition	High	High
Excipient challenge	Low-dose uniformity	Low-dose uniformity plus hydrophobic active distribution
Premium format potential	Moderate	Higher if taste and convenience are solved

Key Takeaways

• Loperamide hydrochloride and simethicone is a mature OTC combination with no meaningful active-ingredient exclusivity.
• The FDA monograph framework, not Orange Book patent protection, is the primary regulatory foundation for conventional products.
• Paragraph IV litigation and biosimilar competition are generally not central risks for a monograph-compliant small-molecule OTC product.
• The best base formulation is a low-cost, immediate-release caplet with strong blend uniformity, rapid disintegration, and moisture-controlled packaging.
• Simethicone dispersion and loperamide content uniformity are the main technical challenges.
• Orally disintegrating and chewable formats offer the strongest formulation-based differentiation but require taste-masking and stability work.
• Patent value is likely to reside in narrow formulation, process, or packaging claims rather than in the active ingredients.
• The most credible commercial opportunities are private-label supply, dual-source manufacturing, travel-oriented packaging, and premium delivery formats.
• Generic and store-brand entry risk is high.
• Manufacturing scale, quality systems, trademarks, distribution, and retailer relationships are more important than legacy active-ingredient patents.

FAQs

Can a company launch a store-brand loperamide and simethicone product without licensing Imodium?

Yes. A company can generally develop a compliant equivalent without licensing the Imodium brand, provided it meets FDA requirements and avoids protected trademarks, trade dress, and enforceable formulation or process rights.

Is simethicone difficult to formulate with low-dose loperamide?

Yes. Simethicone is hydrophobic and can distribute unevenly in a powder blend. The formulation must control segregation, wetting, sticking, and assay uniformity while maintaining rapid tablet disintegration.

Does an orally disintegrating version automatically receive patent protection?

No. Patentability depends on novel and non-obvious technical features. A routine substitution of an orally disintegrating tablet for a conventional tablet may not support durable patent protection.

Is a liquid loperamide and simethicone product commercially attractive?

It can address consumers who cannot swallow tablets, but liquid products face higher formulation, dosing, preservative, stability, and packaging costs. The opportunity is more specialized than the standard caplet market.

What is the most defensible commercial advantage for a new entrant?

The strongest defensible position combines a validated formulation, consistent low-dose manufacturing, reliable simethicone distribution, moisture-protective packaging, retailer access, and a differentiated consumer format.

References

1. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 335: Antidiarrheal drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 332: Antiflatulent drug products for over-the-counter human use. Electronic Code of Federal Regulations.

3. U.S. Food and Drug Administration. (2018). FDA limits packaging for anti-diarrhea medicine loperamide (Imodium) to encourage safe use. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov

5. DailyMed. (2024). Loperamide hydrochloride and simethicone tablet product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov